Trial Watch: Adoptive cell transfer for oncological indications

One particular paradigm of anticancer immunotherapy relies on the administration of (potentially) tumor-reactive immune effector cells. Generally, these cells are obtained from autologous peripheral blood lymphocytes (PBLs) ex vivo (in the context of appropriate expansion, activation and targeting p...

詳細記述

保存先:
書誌詳細
出版年:Oncoimmunology
主要な著者: Aranda, Fernando, Buqué, Aitziber, Bloy, Norma, Castoldi, Francesca, Eggermont, Alexander, Cremer, Isabelle, Fridman, Wolf Hervé, Fucikova, Jitka, Galon, Jérôme, Spisek, Radek, Tartour, Eric, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
フォーマット: Artigo
言語:Inglês
出版事項: Taylor & Francis 2015
主題:
Review
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4590013/
https://ncbi.nlm.nih.gov/pubmed/26451319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1046673
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料